Phaseline

Targets › TOP1

TOP1 (DNA topoisomerase 1): drug programs, companies and trials

33 programs from 27 companies in 350 trials: 172 Phase 2, 91 Phase 1, 85 Phase 3, 2 Phase 4; Oncology, Other, Gastroenterology; next expected readout Nov 2026.

Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme…. (UniProt, P11387)

Open in Phaseline: the race on TOP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaDatopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 4Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer …Dec 2026
AstraZenecaTrastuzumab deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 4BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic …Dec 2026
Sichuan Kelun-Biotech BiopharmaceuticalSacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer …Nov 2026
Gilead SciencesSacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer …Dec 2026
Daiichi SankyoDatopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC …Dec 2026
Daiichi SankyoPatritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) …Dec 2026
Merck & Co. (MSD)Sacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms …Jan 2027
Daiichi SankyoTrastuzumab Deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 3Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer …Mar 2027
Merck & Co. (MSD)Patritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer …May 2028
Luye Pharma GroupLY01610
Topoisomerase I inhibitor (liposomal formulation)
TOP1Phase 3Relapsed Small Cell Lung CancerJun 2028
Alliance for Clinical Trials in OncologyIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 3Pancreatic Adenosquamous CarcinomaDec 2028
National Cancer Institute (NCI)pH Low Insertion Peptide-exatecan Conjugate CBX-12
TOP1 inhibitor conjugate
TOP1Phase 2Metastatic Mismatch Repair Proficient Colorectal Carcinoma; Advanced Malignant Solid NeoplasmDec 2026
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairTopotecan
DNA topoisomerase I inhibitor
TOP1Phase 2SCLCDec 2026
Klus PharmaSacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 2Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian CancerDec 2026
OHSU Knight Cancer InstituteIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 2Pancreatic AdenocarcinomaJan 2027
Taichung Veterans General HospitalNALIRIFOX
Liposomal irinotecan (topoisomerase I inhibitor) in combination with fluorouracil (thymidy
TOP1, TYMSPhase 2Resectable Pancreatic AdenocarcinomaFeb 2027
National Cancer Institute (NCI)Topotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 2Extensive Stage Lung Small Cell Carcinoma; Metastatic Malignant Solid NeoplasmMar 2027
UNC Lineberger Comprehensive Cancer CenterIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Jul 2027
Memorial Sloan Kettering Cancer Centeririnotecan hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 2SarcomaOct 2027
Sun Yat-sen UniversityNALIRIFOX
Combination chemotherapy regimen containing liposomal irinotecan (TOP1 inhibitor), oxalipl
TOP1, TOPO1Phase 2Rectal CancersJun 2028
Shandong Cancer Hospital and InstituteNALIRIFOX
Combination chemotherapy with liposomal irinotecan (topoisomerase I inhibitor), oxaliplati
TOP1, ERCC1Phase 2Pancreatic CancerOct 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineNALIRIFOX
Liposomal irinotecan (SN-38 topoisomerase I inhibitor) combined with fluorouracil and oxal
TOP1Phase 2NENSDec 2028
Children's Oncology GroupIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 2High Risk NeuroblastomaMar 2029
CEBIOTEX7-Ethyl-10-Hydroxycamptothecin (CEB-01)
DNA topoisomerase I inhibitor
TOP1Phase 2Locally Resectable Pediatrics TumorsMay 2029
Targeted Therapy TechnologiesTopotecan
DNA topoisomerase I inhibitor
TOP1Phase 2RetinoblastomaNov 2029
M.D. Anderson Cancer CenterPuxitatug Samrotecan (AZD8205)
Topoisomerase I inhibitor
TOP1Phase 2Adenoid Cystic CarcinomaDec 2029
Mayo ClinicPegylated SN-38 Conjugate PLX038
Pegylated SN-38 conjugate; topoisomerase I inhibitor
TOP1Phase 2Platinum-Resistant Fallopian Tube CarcinomaFeb 2030
Fujifilm Pharmaceuticals U.S.A.Topotecan (FF-10850)
DNA topoisomerase I inhibitor
TOP1Phase 1Advanced Solid Tumors; Retinoblastoma; Pleuropulmonary Blastoma; Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment …Dec 2026
St. Jude Children's Research HospitalIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 1Recurrent Solid TumorDec 2026
National Cancer Institute (NCI)Irinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 1Metastatic Colorectal Carcinoma; Adult Solid NeoplasmMar 2027
National Health Research Institutes, TaiwanIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 1Metastatic Gastric AdenocarcinomaDec 2027
National Institute of Neurological Disorders and Stroke (NINDS)LMP744
Indenoisoquinolone C-MYC/TOPOISOMERASE 1 inhibitor
MYC, TOP1Phase 1Recurrent GlioblastomaDec 2030
City of Hope Medical CenterIrinotecan Hydrochloride
DNA topoisomerase I inhibitor
TOP1Phase 1Recurrent Anaplastic Astrocytoma–

Conditions

Breast Cancer (40) Metastatic Breast Cancer (12) Non-small Cell Lung Cancer (12) Non-Small Cell Lung Cancer (8) Triple Negative Breast Cancer (8) Breast Neoplasms (6) Endometrial Cancer (6) Gastric Cancer (6) HER2-positive Breast Cancer (6) Metastatic Breast Cancer ( HER2 Negative) (5) Advanced Solid Tumor (5) Ovarian Cancer (4)

Modalities

small molecule (16), mixed (11), antibody (3), protein or peptide (1)

Companies

Daiichi Sankyo (3) National Cancer Institute (NCI) (3) AstraZeneca (2) Merck & Co. (MSD) (2) Gilead Sciences (1) St. Jude Children's Research Hospital (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) National Institute of Neurological Disorders and Stroke (NINDS) (1) Klus Pharma (1) Memorial Sloan Kettering Cancer Center (1) National Health Research Institutes, Taiwan (1) Sun Yat-sen University (1) Alliance for Clinical Trials in Oncology (1) Mayo Clinic (1) Fujifilm Pharmaceuticals U.S.A. (1) Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) Targeted Therapy Technologies (1) City of Hope Medical Center (1) UNC Lineberger Comprehensive Cancer Center (1) Shandong Cancer Hospital and Institute (1)

Related targets

TACSTD2 (6) ERBB2 (2) ERBB3 (2) MYC (1) TOPO1 (1) ERCC1 (1) TYMS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.